公开(公告)号：US11931363B2

公开(公告)日：2024-03-19

申请号：US17505271

申请日：2021-10-19

Applicant: Novartis AG

Inventor： Ho Man Chan ,  Xiang-Ju Justin Gu ,  Ying Huang ,  Ling Li ,  Yuan Mi ,  Wei Qi ,  Martin Sendzik ,  Yongfeng Sun ,  Long Wang ,  Zhengtian Yu ,  Hailong Zhang ,  Ji Yue (Jeff) Zhang ,  Man Zhang ,  Qiong Zhang ,  Kehao Zhao

IPC: C07D307/78 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61K45/06 ,  C07D307/79 ,  C07D307/83 ,  C07D487/04

CPC classification number: A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61K45/06 ,  C07D487/04

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder:




wherein R1, R2, R3, R4, R5, and n are as defined herein.

公开(公告)号：US10689378B2

公开(公告)日：2020-06-23

申请号：US16311621

申请日：2017-06-06

Applicant: Novartis AG

Inventor： Ho Man Chan ,  Xingnian Fu ,  Xiang-Ju Justin Gu ,  Ying Huang ,  Ling Li ,  Yuan Mi ,  Wei Qi ,  Martin Sendzik ,  Yongfeng Sun ,  Long Wang ,  Zhengtian Yu ,  Hailong Zhang ,  Ji Yue Zhang ,  Man Zhang ,  Qiong Zhang ,  Kehao Zhao

IPC: C07D471/04 ,  A61P35/00

Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R6, R7 and R8 are as defined herein.

公开(公告)号：US10676479B2

公开(公告)日：2020-06-09

申请号：US16311575

申请日：2017-06-09

Applicant: Novartis AG

Inventor： Ho Man Chan ,  Xingnian Fu ,  Xiang-Ju Justin Gu ,  Ying Huang ,  Ling Li ,  Yuan Mi ,  Wei Qi ,  Martin Sendzik ,  Yongfeng Sun ,  Long Wang ,  Zhengtian Yu ,  Hailong Zhang ,  Ji Yue Zhang ,  Man Zhang ,  Qiong Zhang ,  Kehao Zhao

IPC: C07D487/04 ,  A61P35/00

Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.

公开(公告)号：US11207325B2

公开(公告)日：2021-12-28

申请号：US16863631

申请日：2020-04-30

Applicant: Novartis AG

Inventor： Ho Man Chan ,  Xiang-Ju Justin Gu ,  Ying Huang ,  Ling Li ,  Yuan Mi ,  Wei Qi ,  Martin Sendzik ,  Yongfeng Sun ,  Long Wang ,  Zhengtian Yu ,  Hailong Zhang ,  Ji Yue (Jeff) Zhang ,  Man Zhang ,  Qiong Zhang ,  Kehao Zhao

IPC: A61K31/539 ,  A61K31/343 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  C07D487/04 ,  A61K31/519 ,  A61K45/06

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.

公开(公告)号：US10220036B2

公开(公告)日：2019-03-05

申请号：US15538348

申请日：2015-12-21

Applicant: Novartis AG

Inventor： Ho Man Chan ,  Xiang-Ju Justin Gu ,  Ying Huang ,  Ling Li ,  Yuan Mi ,  Wei Qi ,  Martin Sendzik ,  Yongfeng Sun ,  Long Wang ,  Zhengtian Yu ,  Hailong Zhang ,  Ji Yue (Jeff) Zhang ,  Man Zhang ,  Qiong Zhang ,  Kehao Zhao

IPC: A61K31/539 ,  A61K31/343 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  C07D487/04 ,  A61K31/519 ,  A61K45/06

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.